Selection of Nicotine Therapy to Increase Quitting
A single-blind randomised controlled trial to determine whether smokers who have more choice over which Nicotine Replacement Therapy (NRT) delivery methods they use are more likely to have quit smoking at six months, than smokers with current practice (with NRT available only by patch and/or gum).
Clinical Trials Research Unit, School of Population Health, Auckland University
1,100 participants
Mar 1, 2007
Interventional
Conditions
Summary
Smoking is a major cause of death and disease in New Zealand. Nicotine replacement therapy (NRT) is a key aid to stopping smoking, and can be achieved with patches, gum, inhaler, or tablets. In New Zealand only the patch and gum are subsidised. New ways are urgently needed to get more people to use effective NRT to help them quit. The SONIQ trial will investigate whether smokers who have more choice over which NRT delivery methods they use are more likely to have quit smoking at six months, than smokers with current practice (with NRT available only by patch and/or gum). Smokers in the treatment group will try out the four different forms of NRT for a week, before choosing one or two to use for eight weeks.
Eligibility
Inclusion Criteria1
- Participants will be people from throughout New Zealand who smoke, who contact Quitline (by phone) for smoking cessation advice and assistance. Smokers will be eligible provided they: want to stop smoking within the next two weeks; have their first cigarette within 30 minutes of waking; are able to provide verbal consent; have a telephone.
Exclusion Criteria1
- Pregnant women and women who are breastfeeding will be excluded from the trial. People will also be excluded from the trial if they meet any of the following criteria: current users of NRT products; current users of Zyban (buproprion), clonidine or nortriptyline; use only non-cigarette tobacco products (e.g. pipes, cigars); have had a myocardial infarction within the last three months; and have had unstable or progressive angina pectoris, Prinzmetal’s angina, severe cardiac arrhythmia or a stroke in acute phase.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will be randomised to a selection box of NRT or current practice. Telephone counselling and advice will be available to all participants in the usual manner, via Quitline. Selection box group: Participants will be sent a box containing four different NRT delivery methods, namely patch (21mg), gum (4mg, fruit and mint), inhaler (10mg), and sublingual tablet (2mg), along with a culturally appropriate video/DVD and printed material. Participants will be asked to try out each product over a week prior to their quit attempt. Participants will then be contacted by telephone and asked to choose one or two preferred methods of delivery to use for eight weeks after their Quit day.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12606000451505